How Well Do You Understand the Oral Side Effects of Antipsychotic Medications?

By Ayesha Khan, MD, MBA

Antipsychotic medications, integral in managing psychiatric conditions such as schizophrenia, bipolar disorder, and severe depression, have revolutionized mental health care. However, their widespread use has brought to light unintended side effects, including significant oral health complications.

Recent global health surveys suggest that up to 21% of psychiatric patients experience moderate or severe oral health problems. These complications raise critical concerns for dental health professionals, as managing systemic therapies with oral manifestations requires a multidisciplinary approach.

We'll dive into an evidence-based exploration of how antipsychotic medications affect oral health and the strategies dental professionals can employ for effective management.

Understanding the Link

Antipsychotic drugs are commonly classified into first-generation (typical) and second-generation (atypical) antipsychotics. Both types impact oral health in various ways due to their pharmacodynamic properties, including effects on the central nervous system and peripheral tissues. Commonly prescribed medications such as haloperidol, risperidone, Olanzapine, and quetiapine are associated with a range of oral health complications.

Mechanisms Driving Oral Health Issues

Xerostomia (Dry Mouth):

A prevalent side effect, xerostomia, arises from the anticholinergic properties of many antipsychotics that inhibit salivary secretion. Reduced salivary flow creates an environment conducive to bacterial overgrowth, leading to dental caries, periodontal disease, and halitosis. A study published in the journal Frontiers in Psychiatry (2024) reported that 66% of patients on typical antipsychotics and 53% of patients on atypical antipsychotics experienced moderate to severe xerostomia.

Another significant study documented a marked reduction in unstimulated salivary flow in patients on risperidone and Olanzapine —averaging 0.1-0.15 mL/min compared to 0.3-0.4 mL/min in healthy controls—which correlated strongly with higher caries indices (mean DMFT index of 6.4 versus 3.2 in controls) and plaque accumulation scores over 1.5.

Tardive Dyskinesia and Orofacial Dyskinesias:

These involuntary, repetitive movements of the facial muscles and tongue are commonly seen in patients on long-term antipsychotic therapy. Studies indicate an incidence rate of tardive dyskinesia up to 20-50% after five years of exposure to first-generation antipsychotics, with orofacial involvement present in nearly 80% of cases. These conditions can lead to trauma to oral soft tissues, abnormal wear of teeth (reported in 34% of affected individuals), and compromised oral hygiene practices due to impaired movements.

Hyperglycemia and Diabetes Risk:

Second-generation antipsychotics have been linked to metabolic side effects, such as weight gain and increased risk of diabetes mellitus. Meta-analyses reveal a relative risk of diabetes that is 1.54 times higher among antipsychotic users versus the general population. Poor glycemic control intensifies the risk of periodontal diseases—the bidirectional relationship between diabetes and periodontal health means these patients are doubly susceptible to complications, with an estimated 70% greater likelihood of developing periodontitis.

Altered Immune Response:

Antipsychotic medications can modulate immune functions, increasing the likelihood of opportunistic infections, including oral candidiasis, particularly in patients with xerostomia. Clinical data show that oral candidiasis occurs in about 18% of antipsychotic users (especially Olanzapine) with dry mouth, compared to 7% without medication-induced salivary reduction.

Sialorrhea (Excessive Salivation):

Some antipsychotics, such as clozapine, paradoxically cause sialorrhea, which, though less common than xerostomia, can lead to discomfort, social stigma, and increased risk of aspiration pneumonia. Prevalence estimates suggest that around 30-80% of clozapine users experience clinically significant sialorrhea.

Implications for Dental Professionals

Dental health professionals must recognize the multi-factorial impact of antipsychotic medications on oral health. A meta-analysis published in Oral Health & Preventive Dentistry (2023) highlighted that patients on second-generation antipsychotics had a 1.8-fold increased risk of developing dental caries and a 2.1-fold increased risk of periodontal diseases compared to the general population.

A randomized clinical trial conducted across four psychiatric institutions revealed that 74% of participants on long-term antipsychotic therapy exhibited signs of gingivitis or periodontitis, with severe periodontitis noted in 29% of cases.

This awareness helps tailor customized preventative and therapeutic interventions for patients.

Identification and Assessment

• Detailed History-Taking: Comprehensive medical and drug histories are vital. Dental professionals should identify all prescribed antipsychotic medications, treatment duration, and associated side effects.
• Oral Examination: Regular evaluations for xerostomia, assessing salivary gland function, and screening for mucosal lesions, dental caries, and periodontal disease are necessary. Screening tools for xerostomia, such as the Xerostomia Inventory, have demonstrated sensitivity rates up to 89% in antipsychotic-treated populations.
• Collaboration with Medical Providers: Maintaining close communication with psychiatrists and other healthcare practitioners is critical in understanding the patient’s overall health condition and medication regimen.

Preventative Strategies

Empowering patients with knowledge is foundational. Dental professionals should emphasize the connection between their medication and oral health, stressing the importance of adherence to preventive regimens. Recent research found that structured educational programs increased oral hygiene compliance by 47% in patients with psychiatric conditions. Visual aids, pamphlets, or digital resources can effectively explain these concepts during appointments.

• Saliva Substitutes and Stimulation: Artificial saliva, sugarless chewing gums, and salivary stimulants like pilocarpine can alleviate xerostomia symptoms. A recent randomized trial reported a 44% improvement in perceived dry mouth symptoms among antipsychotic patients using pilocarpine.
• High-Fluoride Products: Prescription fluoride toothpaste or in-office fluoride treatments effectively reduce the risk of caries. Studies show a 28-38% decrease in new caries lesions in this high-risk group when high-fluoride products are used consistently. Customized oral hygiene instructions, including proper brushing and flossing techniques, are particularly beneficial for patients with orofacial dyskinesias.
• Dietary Counseling: Encouraging a reduced intake of cariogenic foods and beverages can curb the progression of dental decay.

Therapeutic Management

1. Frequent Dental Visits: Scheduling biannual or quarterly dental checkups ensures issues like gingivitis or early-stage caries are promptly addressed. A longitudinal study showed a 36% reduction in severe periodontal complications in high-risk patients attending quarterly dental visits.
2. Managing Drug-Induced Dyskinesias: Collaborating with medical practitioners might allow for adjustments in medication regimens or adjunctive therapies to reduce dyskinetic movements. Prophylactic antifungal treatments and regular oral rinses can mitigate fungal infections.
3. Periodontal Therapy: Advanced cases of periodontal disease require scaling, root planing, and possibly surgical interventions.

Future Directions and Research

Emerging technologies in salivary diagnostics hold promise for early detection of medication-induced xerostomia and associated sequelae. Furthermore, the development of antipsychotic drugs with fewer systemic side effects can significantly alleviate the oral health burden on patients. Continuous research and clinical trials are imperative to understand these interactions and enable evidence-based dental care fully.

A Call for Integrated Care

The link between antipsychotic medications and oral health complications underscores the need for a collaborative care approach. By integrating efforts between mental health and dental practitioners, patients on antipsychotic therapy can achieve not only improved psychological well-being but also optimal oral health outcomes. For dental professionals, staying informed about the latest research and evolving care strategies is essential to meet the unique needs of this patient population.

Author: Ayesha Khan, MD, MBA, is a registered physician, former research fellow, and enthusiastic blogger. With a wide range of articles published in renowned newspapers and scientific journals, she covers topics such as nutrition, wellness, supplements, medical research, and alternative medicine. Currently serving as the Vice President of Social Communications and Strategy at Renaissance, Ayesha brings her expertise and strategic mindset to drive impactful initiatives. Follow her blog for insightful content on healthcare advancements and empower yourself with knowledge.

References:

1. Urien, L., Lertxundi, U., Garcia, M., Aguirre, C., Jauregizar, N., & Morera‐Herreras, T. (2025). Oral Adverse Effects of Antipsychotic Medications: A Case/Noncase Analysis of EudraVigilance Data. Oral Diseases.
2. Halder, A., Ravindran, N. P., Nagda, P., Harshe, D., & Harshe, G. (2023). Review of psychotropic agents associated with sialorrhoea, except clozapine. Indian Journal of Psychological Medicine, 45(1), 14-18.
3. Aghasizadeh Sherbaf, R., Kaposvári, G. M., Nagy, K., Álmos, Z. P., Baráth, Z., & Matusovits, D. (2024). Oral health status and factors related to oral health in patients with schizophrenia: A matched case-control observational study. Journal of Clinical Medicine, 13(6), 1584.
4. Urien, L., Jauregizar, N., Lertxundi, U., Fernández, U., & Morera-Herreras, T. (2023). Medication impact on oral health in schizophrenia. Medicina Oral, Patología Oral y Cirugía Bucal, 29(1), e51.
5. Cornett, E. M., Novitch, M., Kaye, A. D., Kata, V., & Kaye, A. M. (2017). Medication-induced tardive dyskinesia: a review and update. Ochsner Journal, 17(2), 162-174.
6. Preshaw, P. M., Alba, A. L., Herrera, D., Jepsen, S., Konstantinidis, A., Makrilakis, K., & Taylor, R. (2012). Periodontitis and diabetes: a two-way relationship. Diabetologia, 55(1), 21-31.
7. Pourjahanshah, D., Nekouei, A. H., Kakoei, S., & Haghdoost, A. (2025). Estimating the cut-off point of Xerostomia Inventory questionnaire score to diagnose dry mouth based on non-stimulating saliva test: a diagnostic sensitivity and specificity study. BMC Oral Health, 25(1), 365.